Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

10.0%

1 terminated/withdrawn out of 10 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
5(55.6%)
Phase 2
2(22.2%)
Phase 3
2(22.2%)
9Total
Phase 1(5)
Phase 2(2)
Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials
NCT07064759Phase 3Recruiting

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Role: lead

NCT06864988Phase 3Active Not Recruiting

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Role: lead

NCT05248230Phase 2Recruiting

4D-710 in Adult Patients With Cystic Fibrosis

Role: lead

NCT05197270Phase 1Recruiting

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Role: lead

NCT05930561Phase 2Active Not Recruiting

4D-150 in Patients With Diabetic Macular Edema

Role: lead

NCT04483440Phase 1Active Not Recruiting

Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia

Role: lead

NCT04517149Phase 1Active Not Recruiting

4D-125 in Patients With X-Linked Retinitis Pigmentosa (XLRP)

Role: lead

NCT05629559Phase 1Recruiting

4D-310 in Adults With Fabry Disease and Cardiac Involvement

Role: lead

NCT04519749Phase 1Active Not Recruiting

An Open-label, Phase 1/2 Trial of Gene Therapy 4D-310 in Adults With Fabry Disease

Role: lead

NCT02994368Terminated

"Natural History" Study of Choroideremia

Role: lead

All 10 trials loaded